IP Library Granted Patent US 10,322,135
Granted Patent B2
US 10,322,135 · App. 15/441,998 · Granted Jun 18, 2019

Pharmaceutical composition comprising indole compound

Inventors: Soon Ha Kim (Daejeon, KR); Hyoung Jin Kim (Daejeon, KR); Heui Sul Park (Daejeon, KR); Seon Yeong Gu (Daejeon, KR); Hyo Shin Kwak (Daejeon, KR); Du Hee Park (Daejeon, KR); Hyo Soo Kim (Daejeon, KR); Hyun Jai Cho (Daejeon, KR); Ji Hyun Kim (Daejeon, KR); Ju Young Kim (Daejeon, KR); Kwang Min Park (Daejeon, KR)
Assignee: LG CHEM, LTD.
A61K31/541A61K8/492A61K31/404A61K31/4184A61K31/427A61K31/496A61K31/497A61Q19/00C07D413/04C07D417/04C07D417/14C07D471/04C07D487/04A61K2800/522
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,322,135
App. No.
15/441,998
Granted
Jun 18, 2019
Kind
B2
Abstract

The present invention relates to a pharmaceutical composition comprising a compound of formula (1), (2) or (3) as defined in the specification for the prevention or treatment of diseases associated with oxidative stress, mitochondria dysfunction, hypoxic injury, necrosis and/or ischemic reperfusion injury, and a cosmetic composition comprising an indole compound having an antioxidant effect.

Claims (3)

1. A method for the treatment of diseases associated with oxidative stress which is mediated by reactive oxygen species (ROS) or reactive nitrogen species (RNS) selected from the group consisting of cardioplegia and myocardial infarction, comprising

administering a composition which comprises a therapeutically-effective amount of (tetrahydropyran-4-yl)- [2-phenyl-5-(1,1-dioxo-thiomorpholin-4-yl)methyl-1H-indol-7-yl]-amine, or pharmaceutically acceptable salt or isomer thereof as an active ingredient; and a pharmaceutically acceptable carrier to a subject in need thereof.

2. The method of claim 1 , wherein the diseases associated with oxidative stress is myocardial infarction.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NO. 13305857 PREVIOUSLY RECORDED AT REEL: 043257 FRAME: 0247. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER AND CHANGE OF NAME . Recorded Sep 20, 2017
From: LG LIFE SCIENCES LTD.
To: LG CHEM, LTD.
Reel/Frame 043710/0909 →
MERGER AND CHANGE OF NAME Recorded Aug 10, 2017
From: LG LIFE SCIENCES LTD.; LG CHEM, LTD.
To: LG CHEM, LTD.
Reel/Frame 043257/0247 →
Priority Claims (2)
KR 10-2009-0101978 · Oct 26, 2009 · national
KR 10-2010-0098511 · Oct 8, 2010 · national
Continuity (2)
Continuation 13503857
Related Publication 20170165272A1 · Jun 15, 2017